Dr Reddy’s introduces Zafirlukast tablets in US – Pharmaceutical Business Review

Dr Reddy's introduces Zafirlukast tablets in US
Pharmaceutical Business Review
Accolate, an oral prescription medicine used to treat asthma, works by blocking substances in the body called leukotrienes, which may contribute to the
Dr Reddy's gets nod to launch ZafirlukastSify
Dr. Reddy's launches generic asthma drug in USMarketWatch
Dr Reddy's gets FDA nod to launch anti-asthma tablets in USEconomic Times
India Infoline.com
all 49 news articles »

View full post on asthma – Google News

Research and Markets: Asthma: An Atlas of Investigation and Management … – Business Wire (press release)

Research and Markets: Asthma: An Atlas of Investigation and Management
Business Wire (press release)
Asthma currently affects more than 150 million people worldwide with almost half of these experiencing symptoms that disrupt their everyday lives.
Research and Markets: Asthma: An Atlas of Investigation and Management Bradenton Herald

all 5 news articles »

View full post on asthma – Google News

Cinryze(R) (C1 esterase inhibitor [human]) Data Presented at 2010 Annual … – Investor’s Business Daily

Cinryze(R) (C1 esterase inhibitor [human]) Data Presented at 2010 Annual
Investor’s Business Daily
MD, of Allergy, Asthma, and Dermatology Associates in Lake Oswego, Ore. discussed the experience of 14 pregnant women who were enrolled in pivotal and
Cinryze® (C1 esterase inhibitor [human]) Data Presented at 2010 Annual Meeting PR Newswire (press release)

all 18 news articles »

View full post on asthma – Google News

Research and Markets: Asthma: Modern Therapeutic Targets

Research and Markets: Asthma: Modern Therapeutic Targets

Research and Markets has announced the addition of the “Asthma: Modern Therapeutic Targets” book to their offering.

The care of an increasing number of adult and child patients with asthma has become a major task for clinicians, and a growing concern for public health physicians and health care administrators. At the same time, and in response to this situation, a considerable effort is being made in basic and clinical research to develop new treatments. This book looks into the future and assesses the possibilities of a number of new therapies for asthma under exploration and development. A group of distinguished international authors examine the potential of new agents working on various targets that are currently under evaluation, including autocoids and their inhibitors, enzyme-inhibitors, sensory nerves and sensory neuropeptides, and receptors in immunology Asthma: Modern Therapeutic Targets provides physicians with an appreciation of the future directions of treatment. It provides clinical pharmacologists and researchers with an up-to-date insight into advances in this exciting field. This book will also be a valuable tool for researchers in the pharmaceutical industry.

Benefits:

* Presents a comprehensive review of current treatment options
* Latest guidelines on clinical management reviewed from an international perspective
* Provides background on pharmacology and mechanisms of drug action
* Provides a key resource for individual patient care

Readership:

* Specialists in respiratory medicine, allergy and immunology
* General physicians
* Clinical pharmacologists
* Doctors in training

Key Topics Covered:

Section I: Autocoids and their receptors in airway diseases

* Adenosine receptors: novel molecular targets in asthma
* The role of transforming growth factors in asthma and their potential as a target for therapy
* The role of transcription factors in asthma: can we modify them for therapeutic purposes?
* Is IKK a feasible therapeutic target for allergic asthma?

Section II: Enzyme inhibitors

* Protease-activated receptors: targets for therapeutic intervention in asthma
* Nitric oxide synthase as a therapeutic target in asthma
* Metalloproteinases and asthma: untried potential for new therapeutic strategies

Section III: Sensory nerves and sensory neuropeptides

* Sensory neuropeptides as innovative targets in asthma
* Rationale for vanilloid receptor 1 antagonist-based therapies in asthma

Section IV: Receptors in immunology

* Anticytokines and cytokines as asthma therapy
* Tumour necrosis factor alpha and asthma
* Are chemokines viable targets for asthma?
* Antagonism of the chemokine receptor CCR3 as a potential therapeutic treatment for asthma

Author:

* R Polosa, Presidio Ospedaliero Ascoli-Tomaselli, Catania, Italy
* ST Holgate, Southampton General Hospital, Southampton, UK

For more information visit http://www.researchandmarkets.com/research/a7c5bf/asthma_modern_the

Contacts

Research and Markets
Laura Wood, Senior Manager,
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOHM adds 6 new asthma, respiratory generic drugs in India – Pharmaceutical Business Review

SOHM adds 6 new asthma, respiratory generic drugs in India
Pharmaceutical Business Review
North American-based SOHM is a generic pharmaceutical manufacturer that produces and markets generic drugs, covering all major treatment categories.
SOHM India Targets $600 Million Generic Drug Market for Asthma and Respiratory MarketWatch (press release)

all 29 news articles »

View full post on asthma – Google News